Compare DexCom, Inc. (DXCM) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while JPMorgan Ultra Short Income ETF trades at $50.47. The key difference: DexCom, Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | JPST | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $89.53 | $50.78 |
52-Week Low | $54.84 | $50.40 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
JPST (JPMorgan Ultra-Short Income ETF) trades at $50.46, showing minimal daily movement with a 0.04% gain. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent institutional filings show growing interest, with Financial Management Professionals increasing their stake by 4.7% in Q2 2026. The fund provides regular dividend distributions, with recent payments of $0.17 per share.
As an ultra-short income ETF, JPST offers stability and income generation in a rising rate environment. The fund's conservative positioning appeals to risk-averse investors seeking cash alternatives. Key risks include interest rate sensitivity and inflationary pressures that could impact short-term bond yields. Institutional accumulation suggests confidence in the fund's strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
